Welcome to our dedicated page for Nuwellis news (Ticker: NUWE), a resource for investors and traders seeking the latest updates and insights on Nuwellis stock.
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology and medical device company centered on precision fluid management for patients with cardio-renal conditions and fluid overload. News about Nuwellis frequently highlights clinical data, regulatory milestones, pediatric innovation, and business updates related to its Aquadex SmartFlow® ultrafiltration system and its Vivian™ pediatric continuous renal replacement therapy (CRRT) platform in development.
Readers of this NUWE news page can follow company announcements on topics such as new patents for extracorporeal safety technologies, NIH grant-supported development of the Vivian pediatric system, and multi-center registries like ULTRA-Peds that examine real-world Aquadex use in critically ill children. Nuwellis also issues news about clinical experiences at hospitals, including studies presented at nephrology conferences that explore Aquadex applications in acute kidney injury, post-cardiac-surgery fluid overload, and complex critical-care cases.
In addition to clinical and technology updates, Nuwellis regularly reports quarterly financial results, at-the-market equity offering arrangements, and other material events through press releases and SEC-referenced communications. These updates provide insight into revenue trends, product launches such as new catheter sizes or circuits, and strategic steps like focusing on U.S. market growth.
Investors, clinicians, and researchers can use this news feed to track how Nuwellis is advancing its Aquadex platform, expanding into pediatric and hospital-based outpatient settings, and progressing the Vivian pediatric CRRT system. Returning to this page allows users to monitor ongoing developments in the company’s cardio-renal strategy, intellectual property portfolio, and regulatory and clinical milestones associated with NUWE.
Nuwellis, Inc. (NASDAQ: NUWE) announced the approval of an equity award under its 2021 Inducement Plan for a new employee, effective September 13, 2021. The award includes an option to purchase 5,965 shares at an exercise price of $4.02, reflecting the stock's closing price on the grant date. The option vests over four years, with 25% vesting after the first year. Nuwellis specializes in medical devices, focusing on the Aquadex SmartFlow® system for treating fluid overload in patients. This award complies with NASDAQ Listing Rule 5635(c)(4), necessitating public notice of non-stockholder approved equity awards.
Nuwellis, Inc. (NASDAQ: NUWE) announced its participation in two upcoming investor conferences. Nestor Jaramillo Jr. and George Montague will represent the company at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 AM ET, and at the Lake Street Capital Markets 5th Annual Best Ideas Growth Conference on September 14, 2021, at 11:00 AM ET. The webcasts will be accessible on Nuwellis’ Investor Relations website, with a replay available for 90 days post-event.
Nuwellis focuses on solutions for patients with fluid overload, featuring the Aquadex SmartFlow system.
Nuwellis, Inc. (NASDAQ: NUWE) announced on August 24, 2021, that independent directors approved equity awards for four new hires under the 2021 Inducement Plan. These awards, as per NASDAQ Listing Rule 5635(c)(4), consisted of options to purchase a total of 42,345 shares of common stock at an exercise price of $4.57 per share, equal to the closing price on the grant date. The options have a ten-year term, vesting over four years, contingent on continued employment. Nuwellis focuses on the Aquadex SmartFlow system for treating fluid overload in patients.
Nuwellis, Inc. (Nasdaq: NUWE) reported record quarterly revenue of $2.5 million for Q2 2021, marking a 35% increase from the previous year. This is the sixth consecutive quarter of double-digit growth, fueled by strong demand for capital equipment and consumables. Notable leadership additions include George Montague as CFO and Neil Ayotte as Senior VP. The company received a Category III CPT code for therapeutic ultrafiltration, effective January 1, 2022. Despite a net loss of $4.7 million, cash reserves remain strong at $24 million with no debt.
Nuwellis (Nasdaq: NUWE) announced plans to develop a pediatric continuous renal replacement therapy (CRRT) device aimed at critically ill children with kidney failure. Supported by a $1.7 million NIH grant, this partnership with Koronis Biomedical Technologies will enhance treatment options for small patients. The device will address limitations in current therapies by improving functionality and reducing complications. The Aquadex SmartFlow® system is already recognized for its benefits in pediatric care, setting the stage for this innovative product to meet urgent medical needs.
Nuwellis, Inc. (NASDAQ: NUWE) will announce its second quarter 2021 financial results on August 10, 2021, at 9:00 AM ET. Following the release, management will host a conference call and webcast to discuss the company's performance and provide a business overview. Interested parties can access the live discussion via the Nuwellis Investors page or by phone. The company specializes in developing the Aquadex SmartFlow® system for ultrafiltration therapy, aimed at helping patients with fluid overload.
Nuwellis announces the issuance of a new Category III CPT code (0692T) for Therapeutic Ultrafiltration, effective January 1, 2022. This code aims to enhance reimbursement for providers using the Aquadex system to treat fluid overload in patients. The code's approval, following validation by the American Medical Association, supports the accessibility of this life-saving therapy. Nuwellis' CEO emphasizes the importance of this milestone for patient access and provider adoption, potentially improving treatment outcomes across the healthcare system.
Nuwellis, Inc. (NASDAQ: NUWE) announced participation in the 2021 Ladenburg Thalmann Healthcare Conference, scheduled for July 14, 2021, at 4:00 pm ET. The event will include a presentation and a fireside chat featuring CEO Nestor Jaramillo and CFO George Montague. An audio webcast will be accessible through Nuwellis’ investor relations website, with a replay available for 90 days post-event. Nuwellis focuses on treating fluid overload through its Aquadex SmartFlow system, which is designed for both adult and pediatric patients when diuretics are ineffective.
Nuwellis, Inc. (NASDAQ: NUWE) announced the approval of an equity award for George Montague as a material inducement for his role as Chief Financial Officer and Treasurer, effective June 30, 2021. Montague received an option to purchase 62,535 shares at an exercise price of $4.20, the closing stock price on the grant date. The options vest over four years, contingent on his continued employment. Nuwellis develops the Aquadex SmartFlow system for ultrafiltration therapy to aid patients with fluid overload, showcasing its commitment to innovative medical solutions.
Nuwellis, Inc. (NASDAQ: NUWE) announced on June 22, 2021, that independent directors approved four equity awards as an inducement for new hires. The awards consist of options to purchase a total of 46,737 shares at an exercise price of $3.98 per share, aligned with the market close on the grant date. The options carry a ten-year term and will vest over four years, with 25% vesting after one year. This decision adheres to NASDAQ Listing Rule 5635(c)(4), necessitating public disclosure of such equity awards.